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8621 articles identified
5458 potentially relevant articles 
3163 excluded at screening
5044 excluded on full-text review
- 2254 mechanistic studies
- 1132 non-Phase 2/3 drug
- 757 not relevant
- 343 description of NAFLD model
- 215 phase 2/3 drug but no data suitable for 
meta-analysis
- 126 other (non-interventional) study type
- 68 not mouse or rat study
- 43 couldn’t obtain full-text
- 41 in vitro or in silico only
- 38 review, commentary, or protocol
- 16 duplicates
- 4 human studies
- 3 not in English
- 2 abstract only
- 2 retracted studies 
414 articles suitable for meta-analysis
(721 cohorts)
414 articles included for meta-analysis
(603 cohorts)
118 cohorts combined due to shared controls
Figure 1. Study inclusion and exclusion flow chart.
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Figure 2. Meta-analysis of hepatic triglyceride content in rodent studies of NAFLD. (A) Forest plot with subgrouping by class of drug. Individual studies
have been hidden and only subgroup summaries are illustrated. Results are expressed as a percentage difference relative to control (/placebo). The
Figure 2 continued on next page
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Figure 2 continued
total number of animals per subgroup is calculated from the sum of control and interventional animals for each subgroup. CI, confidence interval;
DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; GLP-1, Glucagon-like peptide-1; MD, mean difference; LXR, Liver X receptor; PDE,
Phosphodiesterase; PPAR, Peroxisome proliferator-activated receptor; SCD-1, Stearoyl–CoA desaturase-1; SGLT2, Sodium-glucose co-transporter-2;
TUDCA, Tauroursodeoxycholic acid. (B) Meta-regression bubble plot using (log) difference in weight between intervention and control animals, after
removal of studies using models that induce weight loss. (C) Meta-regression bubble plot using (log) difference in fasting insulin between intervention
and control animals, after removal of studies using models that induce weight loss.
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Figure 2—figure supplement 1. Meta-analysis of hepatic triglyceride content in rodent studies of NAFLD by individual drug. Forest plot with
subgrouping by individual drug. Individual studies have been hidden and only subgroup summaries are illustrated. Results are expressed as a
percentage change relative to control (/placebo). Total animals is the sum of control and interventional animals for each subgroup. ARB, angiotensin
receptor blocker; CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; GLP-1, Glucagon-like peptide-1; MD, mean
difference; LXR, Liver X receptor; PDE, Phosphodiesterase; PPAR, Peroxisome proliferator-activated receptor; PUFA; omega-3 polyunsaturated fatty
acid; SCD-1, Stearoyl–CoA desaturase-1; SGLT2, Sodium-glucose co-transporter-2; TUDCA, Tauroursodeoxycholic acid.
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Figure 3. Weight and glucose difference associated with use of each drug class. (A) Box plot illustrating the difference in weight in interventional
animals, expressed as a decimal of the weight of the control animals. Raw data points are plotted for each drug class. (B) Box plot for difference in
fasting glucose in interventional animals, expressed as a decimal of the weight of the control animals. Raw data points are plotted for each drug
class.
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Figure 3—figure supplement 1. Insulin difference associated with use of each drug class and correlation plot of characteristics of studies. (A) Box plot
illustrating the difference in fasting insulin in interventional animals, expressed as a decimal of the weight of the control animals. Raw data points are
Figure 3—figure supplement 1 continued on next page
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Figure 3—figure supplement 1 continued
plotted for each drug class. (B) Plot of Pearson correlation co-efficients (encoded by colour, where red = 1, blue =  1) for continuous traits associated
with each cohort. Traits have been log-transformed prior to analysis. Stars indicate p-value associated with each correlation: ***p<0.001, **p<0.01,
*p<0.05.
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Figure 4. Meta-analysis of steatosis grade in rodent studies of NAFLD. (A) Forest plot with subgrouping by class of drug. Individual studies have been
hidden and only subgroup summaries are illustrated. The total number of animals is calculated from the sum of control and interventional animals for
Figure 4 continued on next page
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Figure 4 continued
each subgroup. CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; GLP-1, Glucagon-like peptide-1; MD, mean
difference; TUDCA, Tauroursodeoxycholic acid. (B) Meta-regression bubble plot using (log) difference in fasting glucose between interventional and
control animals, after removal of studies using models that induce weight loss. (C) Meta-regression bubble plot using (log) difference in fasting insulin
between interventional and control animals, after removal of studies using models that induce weight loss.
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Figure 4—figure supplement 1. Meta-analysis of steatosis grade in rodent studies of NAFLD by individual drug. Forest plot with subgrouping by
individual drug. Individual studies have been hidden and only subgroup summaries are illustrated. Total animals is the sum of control and interventional
animals for each subgroup. ARB, angiotensin receptor blocker; CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; MD,
mean difference; TUDCA, tauroursodeoxycholic acid.
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Figure 5. Meta-analysis of lobular inflammation in rodent studies of NAFLD. (A) Forest plot with subgrouping by class of drug. Individual studies have
been hidden and only subgroup summaries are illustrated. The total number of animals is calculated from the sum of control and interventional animals
for each subgroup. CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; GLP-1, Glucagon-like peptide-1; MD, mean
difference. (B) Meta-regression bubble plot using (log) difference in weight between interventional and control animals, after removal of studies using
models that induce weight loss. (C) Meta-regression bubble plot using (log) fat (%kcal) in diet for each cohort.
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Figure 5—figure supplement 1. Meta-analysis of lobular inflammation in rodent studies of NAFLD by individual drug. Forest plot with subgrouping by
individual drug. Individual studies have been hidden and only subgroup summaries are illustrated. Total animals is the sum of control and interventional
animals for each subgroup. ARB, angiotensin receptor blocker; CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; MD,
mean difference.
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Figure 6. Meta-analysis of hepatocellular ballooning in rodent studies of NAFLD. (A) Forest plot with subgrouping by class of drug. Individual studies
have been hidden and only subgroup summaries are illustrated. The total number of animals is calculated from the sum of control and interventional
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Figure 6 continued
animals for each subgroup. CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; GLP-1, Glucagon-like peptide-1; MD,
mean difference; TUDCA, tauroursodeoxycholic acid. (B) Meta-regression bubble plot using (log) fat (%kcal) in diet for each cohort. (C) Meta-regression
bubble plot using (log) fructose/glucose (% weight) in diet for each cohort. (D) Meta-regression bubble plot using (log) duration of intervention (in
weeks) for each cohort.
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Figure 6—figure supplement 1. Meta-analysis of hepatocellular ballooning in rodent studies of NAFLD by individual drug. Forest plot with
subgrouping by individual drug. Individual studies have been hidden and only subgroup summaries are illustrated. Total animals is the sum of control
and interventional animals for each subgroup. ARB, angiotensin receptor blocker; CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid
X receptor; MD, mean difference; TUDCA, tauroursodeoxycholic acid.
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Figure 7. Meta-analysis of NAFLD Activity Score (NAS) in rodent studies of NAFLD. (A) Forest plot with subgrouping by class of drug. Individual studies
have been hidden and only subgroup summaries are illustrated. k represents the number of cohorts in each subgroup. The total number of animals is
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Figure 7 continued
calculated from the sum of control and interventional animals for each subgroup. CI, confidence interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid
X receptor; GLP-1, Glucagon-like peptide-1; MD, mean difference. (B) Meta-regression bubble plot using (log) difference in weight between
interventional and control animals, after removal of studies using models that induce weight loss. (C) Meta-regression bubble plot using (log) difference
in glucose between interventional and control animals, after removal of studies using models that induce weight loss.
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Figure 7—figure supplement 1. Meta-analysis of NAFLD Activity Score (NAS) in rodent studies of NAFLD by individual drug. Forest plot with
subgrouping by individual drug. Individual studies have been hidden and only subgroup summaries are illustrated. k represents the number of cohorts
in each subgroup. Total animals is the sum of control and interventional animals for each subgroup. ARB, angiotensin receptor blocker; CI, confidence
interval; DPP4, Dipeptidyl peptidase-4; FXR, Farnesoid X receptor; MD, mean difference.
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Figure 8. Meta-analysis of fibrosis stage in rodent studies of NAFLD. (A) Forest plot with subgrouping by class of drug. Individual studies have been
hidden and only subgroup summaries are illustrated. The total number of animals is calculated from the sum of control and interventional animals for
each subgroup. CI, confidence interval; FXR, Farnesoid X receptor; GLP-1, Glucagon-like peptide-1; MD, mean difference. (B) Meta-regression bubble
plot using (log) difference in weight between interventional and control animals, after removal of studies using models that induce weight loss.
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Figure 8—figure supplement 1. Meta-analysis of fibrosis stage in rodent studies of NAFLD by individual drug. Forest plot with subgrouping by
individual drug. Individual studies have been hidden and only subgroup summaries are illustrated. Total animals is the sum of control and interventional
animals for each subgroup. CI, confidence interval; FXR, Farnesoid X receptor; MD, mean difference.
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Figure 9. Funnel plots illustrating study distribution bias from meta-analyses of histological features. (A) Funnel plot illustrating study distribution
(publication) bias in 145 original studies (solid grey circles) with 54 added studies (from trim-and-fill) for meta-analysis of steatosis grade. The statistical
significance associated with each study is illustrated with the coloured background. Egger’s test p-value indicates the likelihood that the original studies
came from a symmetrical distribution. (B) Funnel plot for lobular inflammation meta-analysis with 103 original studies and 42 added studies. (C) Funnel
plot for fibrosis stage meta-analysis with 34 original studies and 14 added studies. (D) Funnel plot for NAS meta-analysis with 106 original studies and
43 added studies.
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Figure 9—figure supplement 1. Quality assessment of included cohorts. (A) Distribution of overall quality scores
from a four-point scale, composed of the use of a power calculation, use of blinding, randomisation, and referring
to a predefined protocol, with 1-point awarded for presence of each factor. (B) Proportion of cohorts achieving
each factor is shown in B.
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Figure 10. Summary of univariable meta-regression results across all outcomes.
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